## Contents

### Introduction
A retrospective and prospective overview of the investigations on amyloid and amyloidosis – the β-fibrillloses

*G. G. Glenner*

3

### General subjects

Clinical implications of differentiating the common forms of generalized amyloidosis; a re-examination of an old idea

*J. R. Wright, E. Calkins and A. I. Ozdemir*

17

Histochemical and serological differentiation of human amyloidosis

*M. H. van Rijswijk, C. W. G. J. van Heusden and L. Ruinen*

25

Immuno-histological diagnosis and classification of amyloidosis

*Y. Levo, N. Livni and A. Laifer*

35

SAA amyloid protein levels in amyloid-prone chronic inflammatory disorders

*C. Svartman, A. Masuda, M. D. Benson and M. A. Scheinberg*

38

Serum amyloid A: monitor of cancer dissemination. Comparison with other serum acute phase reactive proteins

*C. J. Rosenthal, C. Noguera, O. Platica and L. Sullivan*

43

Immunohistochemical staining of normal and pathological human tissues with antibody to serum amyloid P-component (SAP)

*R. F. Dyck, M. Kershaw, N. McHugh and M. B. Pepys*

50

Amyloid-like substances in cartilage of the sterno-clavicular joint

*F. Uchino, H. Nakamura, T. Kamei and T. Nagasawa*

55

Amyloid degrading activity of human serum

*I. Kedar, M. Ravid and E. Sohar*

60

Discussion

63

### Hereditary amyloidosis syndromes

Familial amyloidotic polyneuropathy in Japanese. Clinical, pathophysiological, biochemical, and therapeutic studies

*S. Araki, T. Kurihara, S. Tawara and T. Kuribayashi*

67

Preliminary report on a recently discovered family of Swedish origin with heredofamilial amyloid polyneuropathy

*A. S. Cohen, A. Rubinow, D. Ginter and F. Wilson*

78
Systemic amyloidosis in an American family of Swedish origin: histological and biochemical studies

M. D. Benson

Forty years of experience with Type I amyloid neuropathy. Review of 483 cases

P. Coutinho, A. Martins da Silva, J. Lopes Lima and A. Resende Barbosa

Clinical evaluation of late onset cases in Type I (Andrade) amyloid neuropathy

A. Bastos Lima and A. Martins da Silva

Defective cardiovascular autonomic responses in familial amyloidotic polyneuropathy

A. Falcão de Freitas, S. Azevedo and L. Maciel

Biochemical aspect of sympathetic neuronal dysfunction in familial amyloid polyneuropathy

T. Suzuki, S. Higa, S. Sakoda, A. Hayashi, Y. Yamamura, Y. Takaba and A. Nakajima

DBH activity in FAP patients and siblings – first results

M. L. P. Sales-Luís, M. Azevedo and C. Manso

Evidence for high incidence of HLA-A2 and HLA-A9 in patients afflicted with Type I (Andrade) amyloid neuropathy – preliminary studies

B. Martins da Silva, M. Manuel Santarém and M. P. Araújo-Chaves

Discussion

Ultrastructure of skin biopsies from patients with heredofamilial amyloid polyneuropathy

T. Shirahama, A. S. Cohen, A. Rubinow and O. G. Rodgers

Pathology of the autonomic nervous system in Andrade type of familial amyloidotic polyneuropathy. Study of 11 postmortem cases

A. Guimarães, L. Monteiro and P. Coutinho

Prealbumin and amyloid in the Portuguese type of familial amyloidotic polyneuropathy

P. P. Costa, A. S. Figueira, F. R. Bravo and A. Guimarães

Clinical and biochemical studies on Ogawa Village type hereditary amyloidosis with DMSO therapy

S. Kito, E. Itoga, Y. Ito, T. Kishida, Y. Yamamura, T. Shinoda and Y. Yaguchi

Chemical characterization of amyloid fibril proteins in hereditary amyloidosis

T. Shinoda, Y. Yaguchi, S. Kito, E. Itoga and Y. Ito
Variable incidence of amyloidosis in FMF patients of different Jewish ethnic groups
   M. Pras, J. Gafni and N. Bronshpigal

Discussion

174

Clinical aspects of acquired syndromes

Experience with an amyloid clinic
   C. R. Tribe, P. A. Bacon and J. C. Mackenzie

Follow-up study of amyloidosis secondary to rheumatic disease
   O. Wegelius, F. Wafin, H. M. Falck and T. Törnroth

Renal amyloidosis in rheumatic disease: a clinicopathological correlative study
   T. Törnroth, H. M. Falck, F. Wafin and O. Wegelius

HLA antigens in amyloidosis secondary to rheumatoid arthritis
   A. Pasternack, A. Tillikainen and S. Koskimies

The HLA antigens in patients with amyloidosis secondary to rheumatic diseases
   F. Wafin, O. Wegelius, H. M. Falck and S. Koskimies

Juvenile amyloidosis in the Ange peoples of Papua New Guinea
   K. P. W. J. McAdam, P. Westermark, R. F. Anders and A. Vollcr

Deviations from expected patterns in AA-amyloidosis
   M. Pras, J. Gafni and E. C. Franklin

Discussion

191

200

205

207

211

215

Senile cardiac amyloidosis
   P. Westermark, G. G. Cornwell III, B. Johansson and J. B. Natvig

Microscopic amyloidosis of the heart valves: A common local complication of chronic damage and scarring
   Y. Goffin

Cerebral amyloid angiopathy
   T. I. Madybur

Localized cutaneous amyloidosis. A clinical review of 100 cases including immunofluorescent studies
   D. M. MacDonald, P. E. Fergin and M. M. Black

Esophageal motor dysfunction in systemic amyloidosis
   A. Rubinow, L. D. Harris and A. S. Cohen

Isolated giant hepatomegaly. A clinical marker for AL-kappa amyloidosis
   M. Pras, B. Frangione and E. C. Franklin

Discussion

226

231

239

243

249

253
Amyloid fibrils (proteins and precursors)

Structure and antigenic analysis of light chain amyloid proteins
  J. B. Natvig, P. Westermark, K. Sletten, G. Husby and T. Michaelsen 257

The structure of amyloid proteins
  G. Husby and K. Sletten 266

Conformational variable (parameter) analysis of amyloid fibril and some other proteins
  T. J. Muckle and C. H. Goldsmith 274

Possible deposition in tissue of amyloid protein in a nonfibrillar form
  T. Shirahama, M. Skinner and A. S. Cohen 278

Similarities between cytoskeletal ‘intermediate’ 10-nm filaments and amyloid
  E. Linder 283

The dissociation of secondary amyloid fibrils into constituents related to serum amyloid protein and apolipoprotein
  J. B. Lian, M. Aviram, M. Skinner, A. S. Cohen and R. S. Lees 288

Discussion 299

Polymorphism of SAA within human high density lipoprotein
  K. P. W. J. McArdern, L. L. Bausserman, P. N. Herbert and K. M. Green 302

Immunohematological investigations on serum amyloid A (SAA). Temperature-induced changes of its quaternary structure
  R. P. Linke 313

Secondary amyloid fibril fractions of molecular weight greater than AA protein. Immunohematological and biochemical characterization
  P. D. Gorevic, G. Lavie, A. I. Pick, M. Pras, B. Frangione and E. C. Franklin 320

Characterization of an amyloid protein AA similar to SAA
  T. Isobe, G. Husby and K. Sletten 331

Primary structure of human amyloid-related serum protein SAA
  G. Marhaug, K. Sletten and G. Husby 337

Variations of the kidney lesions and of protein AA in secondary systemic amyloidosis
  P. Westermark, K. Sletten and M. Eriksson 343

Significance of ionic strength in the immunodiffusion with anti-AA
  T. Isobe 348

Amyloid-related Bence Jones proteins bind dinitrophenyl L-lysine (DNP)
  J. Bertram, R. J. Gualtieri and E. F. Osserman 351
The calcium-dependent interaction of blood clotting factors with primary amyloid fibrils

M. Skinner, L. Talarico, A. S. Cohen and A. St. John

Ultrastructural studies and partial characterization of a low molecular weight component of senile cardiac amyloid fibrils

P. D. Gorevic, A. B. Cleveland, J. R. Wright, D. Zucker-Franklin, B. Frangione and E. C. Franklin

Studies of serum amyloid P-component (SAP) in man and animals


Studies on amyloid protein AP


Discussion

Models of pathogenesis

Origin of protein AA

E. P. Benditt, N. Eriksen and J. S. Hoffman

In vitro synthesis by human granulocytes of an amyloid A antigenically related component

C. J. Rosenthal and W. Brissette

A pathogenetic role for polymorphonuclear leukocytes in the synthesis and degradation of SAA protein

S. L. Silverman, E. S. Cathcart, M. Skinner, A. S. Cohen and L. Burnett

Amyloidogenesis in primary skin amyloidoses

K. Hashimoto and H. Kobayashi

Pathogenesis of amyloidosis. Ultrastructural aspects of cell membrane in amyloidogenesis and amyloid fibril destruction

S. Nakagawa

Characterization of a series of elastase-like serine proteases on human peripheral blood monocytes that degrade SAA

G. Lavie, E. C. Franklin and D. Zucker-Franklin

Evidence for the degradation of serum amyloid A (SAA) on the surface of mononuclear leukocytes

D. Zucker-Franklin, G. Lavie and E. C. Franklin

Do peripheral blood monocytes play a role in the degradation of immunoglobulin light chain to an AL-like protein?

R. Mornaghi, G. Lavie, B. Frangione and E. C. Franklin
Degradation of protein SAA to an AA-like fragment by enzymes of monocytic origin

*B. Skogen, L. Thorsteinsson and J. B. Natvig* 465

Heterogeneity among AA proteins in experimentally induced murine amyloid

*J. Loewenstein, A. Rimon and A. Frensdorff* 471

Discussion 475

Fractionation of degraded amyloid material from a patient with secondary amyloidosis performed wholly in sodium hydroxide

*A. F. Strachan and P. M. Johnson* 477

Pathogenical studies in casein-induced amyloidosis of the liver in hamsters (*Mesocricetus auratus*)

*E. Gruys* 482

In vitro production of SAA by mouse hepatocytes

*M. J. Selinger, K. P. W. J. McAdam, M. M. Kaplan, J. D. Sipe, D. Rosenstreich and S. N. Vogel* 486

Amyloid resistance in A/J mice: transfer to a susceptible strain

*J. R. Wohlgemuth, E. S. Cathcart, M. Bennett and M. S. Lavers* 491

Induction of murine amyloidosis by the cadmium ion

*J. Loewenstein, M. Greenwald, H. Mazursky, A. Frensdorff and A. Rimon* 495

Experimental murine amyloidosis induced by *Candida albicans*

*A. Savage and C. R. Tribe* 499

Discussion 504

Detection of a macrophage-derived mediator for the acute phase serum amyloid A (SAA) response of mice to endotoxin

*J. D. Sipe, S. N. Vogel, D. L. Rosenstreich and K. P. W. J. McAdam* 505

Amyloid resistance in mice correlates with the degree of macrophage activation

*G. I. Fliho and M. A. Scheinberg* 513

Variations in the susceptibility of different strains of mice to the development of amyloidosis and the production of SAA

*G. Levis, E. Flechner, G. Gallo, B. Frangione and E. C. Franklin* 518

Granulocytes and T-lymphocytes in casein-induced murine amyloidosis

*I. Kedar and M. Ravid* 524

Biological characterizations of amyloid enhancing factor

*M. A. Axelrad and R. Kisilevsky* 527

xviii
Studies of serum amyloid P-component (SAP) as an acute phase reactant in mice
   M. L. Beltz, S. L. Rogers, K. Gomer, A. J. S. Davies,
   M. J. Doenhoff, G. G. B. Kleus and M. B. Peps  534

Canine cyclic hematopoiesis (CH dogs): Animal model of systemic amyloidosis
   E. A. Machado, P. D. Gorevic and J. B. Jones  543

Bovine renal secondary amyloidosis
   E. Gruys  554

Discussion  559

Treatment of various syndromes

Further studies of therapy of amyloidosis with dimethylsulfoxide (DMSO)
   E. F. Osseman, W. H. Sherman and R. A. Kyle  563

Successful treatment with dimethylsulfoxide of human amyloidosis secondary to rheumatoid arthritis
   M. H. van Rijswij, L. Ruinen, A. J. M. Donker, J. Marrink,
   Th. Ockhuizen, J. J. de Blécourt and E. Mandema  570

Prolonged dimethylsulfoxide treatment of systemic amyloidosis in man
   M. Ravid and I. Kedar  578

Daily prophylactic colchicine in familial Mediterranean fever
   D. Zemer, M. Pras, Y. Shemer, E. Sohar and J. Gafni  580

The effect of colchicine and dimethylsulfoxide (DMSO) on the genetic amyloidosis of the white Pekin duck
   M. Greenvald, I. Kedar and E. Sohar  584

Renal transplantation in FMF amyloidosis
   E. Jacob, Z. Shapira, D. Zemer and J. Gafni  587

Treatment of amyloidosis secondary to rheumatoid arthritis with cyclophosphamide
   H. M. Falck, B. Skrifvars and O. Wegelius  592

Discussion  595

Conclusion

Final summation
   A. S. Cohen  599

Subject index  607
Index of authors  627